Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public Plan Would Improve Market, Sebelius Testifies At House Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS secretary endorses the principles behind the House discussion draft on health care reform during a June 24 hearing; Sebelius’ statements on public option echo President Obama’s press conference from the day before.

You may also be interested in...



HELP Health Reform Bill On Fast Track With Gaps To Fill; Dodd Takes Reins

The Senate Health, Education, Labor and Pensions Committee's health care reform bill is headed to markup beginning June 16, although details of key provisions, including establishment of a public insurance option, are still being developed

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel